scholarly journals Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone

2016 ◽  
pp. 417
Author(s):  
Gian Luigi Gigli ◽  
Stefano de Biase ◽  
Mariarosaria Valente
Keyword(s):  
Restless Legs Syndrome ◽  
Prolonged Release ◽  
Restless Legs

scholarly journals The role of BTBD9 in the cerebral cortex and the pathogenesis of restless legs syndrome

2020 ◽  
Vol 323 ◽  
pp. 113111 ◽  
Author(s):  
Shangru Lyu ◽  
Hong Xing ◽  
Mark P. DeAndrade ◽  
Pablo D. Perez ◽  
Keer Zhang ◽  
...  
Keyword(s):  
Cerebral Cortex ◽  
Restless Legs Syndrome ◽  
Restless Legs

scholarly journals 0790 The Clinical Significance of Hepcidin as a Predictive Value for Treatment Responses in Restless Legs Syndrome

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A300-A301
Author(s):  
H Im
Keyword(s):  
Restless Legs Syndrome ◽  
Iron Homeostasis ◽  
Dependent Manner ◽  
Healthy Controls ◽  
Restless Legs ◽  
Inflammatory Processes ◽  
Drug Naïve ◽  
Therapeutic Responses

Abstract Introduction Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. Hepcidin is the key regulatory hormone of systemic iron homeostasis and is related to inflammatory processes. We aimed to evaluate the clinical utility of hepcidin as a diagnostic biomarker and index of therapeutic responses in RLS patients after dopaminergic treatment. Methods Non-anemic and drug-naive RLS patients (n=18) and healthy controls (n=15) were enrolled. Hepcidin (pre-prohepcidin) and iron-related values in serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 RLS patients. Information about sociodemographic characteristics, sleep-related profiles, mood, and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results Hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at a diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/ml, p = 0.978). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression, and anxiety. Conclusion This study demonstrates a role of hepcidin as a predictor of therapeutic responses in RLS patients. Support This work was supported by the Korea Health technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, South Korea [grant number HI17C2072].

scholarly journals Recurrent CSPs after Transcranial Magnetic Stimulation of Motor Cortex in Restless Legs Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Aulikki Ahlgrén-Rimpiläinen ◽  
Hannu Lauerma ◽  
Seppo Kähkönen ◽  
Juha Markkula ◽  
Ilpo Rimpiläinen
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Motor Cortex ◽  
Restless Legs Syndrome ◽  
Magnetic Stimulation ◽  
Silent Period ◽  
Feedback Regulation ◽  
Conduction Time ◽  
Restless Legs ◽  
Abductor Digiti Minimi

Aims.The aim of this study was to investigate the motor control and central silent period (CSP) in restless legs syndrome (RLS).Methods.Transcranial magnetic stimulation was focused on the dominant and nondominant hemispheric areas of motor cortex in six subjects with RLS and six controls. The responses were recorded on the contralateral abductor digiti minimi (ADM) and tibialis anterior (TA) muscles with intramuscular needle electrodes.Results.No significant differences were found in the motor conduction or central motor conduction time, in the latency, or in the duration of the CSPs between or within the groups, but multiple CSPs were observed in both groups. The number of the CSPs was significantly higher in both ADMs and in the dominant TA (P≤0.01) in the RLS group compared to the controls.Conclusion.Descending motor pathways functioned correctly in both groups. The occurrence of the recurrent CSPs predominantly in the RLS group could be a sign of a change of function in the inhibitory control system. Further research is needed to clarify the role of the intramuscular recording technique and especially the role of the subcortical generators in the feedback regulation of the central nervous system in RLS.

The role of iron in restless legs syndrome

2007 ◽  
Vol 22 (S18) ◽  
pp. S440-S448 ◽  
Author(s):  
Richard P. Allen ◽  
Christopher J. Earley
Keyword(s):  
Restless Legs Syndrome ◽  
Restless Legs

scholarly journals Changes in Hepcidin Serum Levels Correlate with Clinical Improvement in Idiopathic Restless Legs Syndrome Patients

2020 ◽  
Vol 9 (12) ◽  
pp. 4115
Author(s):  
Hee-Jin Im ◽  
Jee Hyun Kim ◽  
Chang-Ho Yun ◽  
Dong Wook Kim ◽  
Jeeyoung Oh
Keyword(s):  
Dopamine Agonist ◽  
Clinical Improvement ◽  
Restless Legs Syndrome ◽  
Serum Levels ◽  
Dependent Manner ◽  
Healthy Controls ◽  
Restless Legs ◽  
Serum Hepcidin ◽  
Drug Naïve

Background: Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron–dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. Methods: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. Conclusions: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.

Sign in / Sign up

Export Citation Format

Share Document